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Introduction Heated tobacco products (HTPs) are being marketed in several countries around the world with claims that they are less harmful than combusted cigarettes, based on assertions that they expose users to lower levels of toxicants. In the USA, Philip Morris International (PMI) has submitted an application to the Food and Drug Administration (FDA) in 2016 seeking authorisation to market its HTPs, IQOS, with reduced risk and reduced exposure claims. Methods We examined the PMI's Perception and Behavior Assessment Studies evaluating perceptions of reduced risk claims that were submitted to the FDA and made publicly available. Results Qualitative and quantitative studies conducted by PMI demonstrate that adult consumers in the USA perceive reduced exposure claims as reduced risk claims. Conclusion The data in the PMI modified risk tobacco product IQOS application do not support reduced risk claims and the reduced exposure claims are perceived as reduced risk claims, which is explicitly prohibited by the FDA. Allowing PMI to promote IQOS as reduced exposure would amount to a legally sanctioned repeat of the 'light' and 'mild' fraud which, for conventional cigarettes, is prohibited by the US law and the WHO Framework Convention on Tobacco Control.
InTRoduCTIon
Heated tobacco products (HTPs), also called heatnot-burn products, are tobacco products that heat tobacco to temperatures that avoid combustion and produce a nicotine aerosol that is inhaled by smokers and may also generate side-stream emissions. 1 As of February 2018, HTP entrants into the global market included Philip Morris International's (PMI)'s 'IQOS', British American Tobacco's 'Glo', Japan Tobacco's 'Ploom Tech' and RJ Reynolds' revamped 'Eclipse'. Because of the growing evidence of severe negative health effects of smoking and smokers' concerns about their health, tobacco companies have been motivated to create 'safer cigarettes' since the 1960s, and in 1988 they first introduced HTPs, marketing them as less harmful than combusted cigarettes. While HTPs produce different toxic chemicals than combusted cigarettes, 2 the human health effects of HTPs are not completely understood and the evidence that PMI submitted to the US Food and Drug Administration (FDA) revealed that, in terms of the clinical biomarkers of disease 3 or pulmonary and immune toxicity, 4 IQOS was not significantly different from cigarettes.
As of February 2018, the new HTPs, like PMI's IQOS, were being sold in multiple countries around the world in minimalist high-tech looking stores that resemble Apple stores. [5] [6] [7] Advertisements and marketing materials for IQOS emphasise both its superiority over combustible cigarettes (in terms of cleanliness and customisability) and similarity to them (in terms of product's taste, size and providing similar behavioural experience). 6 Claims about health benefits or lower risks of IQOS are not emphasised in the marketing materials and some of the materials carry minimal health warnings, such as 'This tobacco product can harm your health and is addictive' 6 or it is 'not risk-free or a safe alternative to cigarettes but it is a much better choice than smoking.' 7 Before IQOS is introduced into the US market, PMI needs the FDA's permission. The 2009 Family Smoking Prevention and Tobacco Control Act 8 (FSPTCA) assigns the FDA authority to regulate the manufacturing, marketing and distribution of tobacco products in the USA. Tobacco manufacturers may seek authorisation from FDA to market products with claims that they reduce risks of tobacco-related diseases compared with other tobacco products currently on the market.
To obtain FDA authorisation to market a product as a 'modified risk tobacco product' (MRTP), a company must submit an MRTP application to FDA. FDA may issue one of two types of orders permitting such marketing: (1) a 'risk modification order' or (2) an 'exposure modification order'. 9 10 For a risk modification order, a company must provide scientific evidence that the product 'as actually used by consumers will (1) significantly reduce harm and the risk of tobacco-related disease to individual users and (2) benefit the health of the population as a whole taking into account both users of tobacco products and persons who do not currently use tobacco products.' 10 When such scientific evidence is not available and cannot be obtained without long-term epidemiological studies, an exposure modification order can be issued if the company demonstrates that such an order would be appropriate for promoting public health (once again taking into account both users and non-users) and that lower levels of harmful chemicals in the product will likely result in reduced death and disease among individual tobacco users. Under the exposure modification order, the marketing claim can only state that the product has lower levels of or is free of a certain substance. Furthermore, a company needs to demonstrate that "consumers will not be misled into believing that the product is […] less harmful or presents […] less of a risk of disease than Manager of Marlboro from 1969 to 1972 , James] Morgan, Philip Morris made a calculated decision to use the phrase 'lower tar and nicotine' even though its own marketing research indicated that consumers interpreted that phrase as meaning that the cigarettes not only contained comparatively less tar and nicotine, but also that they were a healthier option." 24 Para 2402, p. 888 "Morgan, who later became CEO of Philip Morris, further explained in 2002 that rather than relying on the tar and nicotine numbers from the FTC Method, 'the major influence in people's perceptions in the tar of a cigarette would have come from the marketing positioning of a brand as opposed to people literally reading the FTC [tar and nicotine figures]." 24 Para 2403, p. 888
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Philip Morris and the other tobacco companies knew that "many smokers who were concerned and anxious about the health risks from smoking would rely on the health claims made for low tar cigarettes as a reason, or excuse, for not quitting smoking" 24 Para 2627, p. 971 one or more other commercially marketed tobacco products." 9 The FSPTCA puts the burden on the MRTP applicant, not the FDA, to demonstrate that the product presents reduced risk or reduced exposure and to demonstrate that consumers do not perceive reduced exposure claims as reduced risk claims.
Long before the MRTP process was enacted in 2009, tobacco companies had been misleading the public with reduced exposure claims since the 1950s, asserting that filtered and low-tar cigarettes 11 gave smokers 'less tar and nicotine', 12 a reduced exposure claim. 'Light' and 'mild' cigarettes have been marketed to smokers concerned about their health and positioned as an alternative to quitting smoking. [13] [14] [15] Even though advertisements for light and mild cigarettes almost never explicitly stated that they would reduce risk of tobacco-related disease, people who saw these advertisements with reduced exposure claims perceived these cigarettes to have lower health risks than regular cigarettes. 16 17 Furthermore, these cigarettes did not result in lower levels of exposure to harmful chemicals for users. Tobacco companies created them with microscopic ventilation holes in the filters to draw in air and reduce machine-measured tar and nicotine, which gave the appearance that these products delivered lower emissions to the user. 18 19 However, the cigarette companies designed these products so that smokers would compensate for dilution of the smoke by blocking ventilation holes with their lips, taking larger puffs or taking more frequent puffs. [20] [21] [22] [23] This inherently deceptive nature of reduced exposure and reduced risk ('light' and 'mild') marketing claims was at the core of the US Department of Justice's Racketeer Influenced and Corrupt Organization (RICO) Act lawsuit against the major cigarette companies for defrauding the public about the dangers of smoking and which essentially became the basis of the FSPTCA's MRTP provisions. In August 2006, Federal Judge Gladys Kessler held 24 that the tobacco companies, including Philip Morris, violated RICO by fraudulently covering up the health risks associated with smoking and for marketing their products to children. Judge Kessler found that the companies "have engaged in and executed -and continue to engage in and execute --a massive 50 year scheme to defraud the public, including consumers of cigarettes, in violation of RICO [emphasis added]." In her 1683page opinion with extensive Findings of Fact, Judge Kessler found, among other fraudulent acts, that Philip Morris and other tobacco companies deceptively marketed cigarettes characterised as 'light' or 'low tar', while knowing that those cigarettes were at least as hazardous as 'full flavoured' cigarettes; misled smokers, former smokers and non-smokers to believe that these cigarettes were safer and deliberately targeted the youth market (see table 1 for examples of relevant findings). Importantly, the court found that there was a reasonable likelihood that defendants would continue to violate RICO in future.
Following the 2006 RICO decision, in 2009, Congress recognised and described the tobacco companies' use of reduced exposure claims to mislead the public and Judge Kessler's findings in 14 of the 49 Findings for the FSPTCA. 10 Of particular relevance, Congressional Finding 40 states: "The dangers of products sold or distributed as modified risk tobacco products that do not in fact reduce risk are so high that there is a compelling governmental interest in ensuring that statements about modified risk tobacco products are complete, accurate, and relate to the overall disease risk of the product."
Given the long history of the tobacco industry using reduced exposure claims to mislead consumers into believing that the products in question have reduced risk, most notably through the use of 'light' and 'mild' cigarette claims, it is important to evaluate to what extent the modified risk claims for the new HTP products are based on scientific evidence and whether reduced exposure claims are perceived by consumers as reduced risk claims. This paper uses the materials in the PMI MRTP application made public by the FDA to evaluate these claims.
MeThods
We examined the materials in the PMI MRTP applications to FDA 25 for its HTP IQOS system and Heatstick products (PMI also refers to IQOS as Tobacco Heating System (THS) 2.2 in these materials). On 5 December 2016, PMI submitted its MRTP applications asking the FDA to authorise marketing of IQOS with reduced risk and reduced exposure claims. Our analysis is based on the Executive Summary 26 
ResulTs
To develop and evaluate marketing messages and materials with reduced risks and reduced exposure claims, PMI conducted Consumer PBA Studies (table 2) . Participants were recruited by phone from proprietary databases maintained by local research agencies, which include people interested in participating in market research. Participants' smoking status was based on self-report.
Qualitative studies
PMI's qualitative studies (THS-PBA-02-US and THS-PBA-04-US) were conducted by TNS Qualitative. Focus groups and individual interviews were conducted in person, in facilities with one-way mirrors with PMI representatives observing the studies. They followed discussion guides and employed 'visual aids' to position products on relative risk and interest to use scales. Focus groups lasted 2.5 hours, while individual interviews took 1.5 hours. Participants evaluated various messages containing either reduced exposure or reduced risk claims. In THS-PBA-02-US, they evaluated 13 messages in focus groups in Phase 1 (Online Supplementary 1), which were subsequently modified into seven messages for testing with individual interviews in Phase 2 (Online Supplementary 2). Participants frequently equated reduced exposure claims with reduced risk, conflating the reduction in chemicals with lower chances of developing tobacco-related health issues. For example, female smoker (21-34 years old, Phoenix) stated: "It reduces your body's exposure to the chemicals… that would be my biggest take-away… it suggests that it is better for you than a traditional cigarette." When asked to clarify: (Better-In what way?), she specified: "It's the lesser of two evils; it's a better bad choice… It reduces harmful chemicals which is likely to reduce your chances of getting a tobacco-related disease."
While the PMI's claims that reduced exposure does not mean reduced harm tried to address this issue, some people found this juxtaposition of a claim of reduced exposure and no reduced harm confusing and hard to believe, which reduced credibility of the message source. Female smoker (21-35 years old, Boston) explained: "It says to me that if you smoke this or if you use this thing, you're still at risk of getting all those diseases that they claim it reduces your exposure to… The way it's worded… I'm not buying into it. It's kind of doubletalk… […] It's flip flopping, saying it will reduce but you still might get it, or … It's just weird, it doesn't make me want to use it at all, now that I'm reading this… This makes me less likely to use it, because I'm… almost mad that it tries to claim that it… has benefits, but it really doesn't."
The THS-PBA-02-US Study report concludes that all messages (both reduced risk and reduced exposure claims) were perceived by participants as statements about lower harm. In Phase 2, three out of seven messages were reduced exposure claims. For all three reduced exposure messages, the PMI's report stated that participants perceived IQOS to be a lower risk than conventional cigarettes because the tobacco is heated, not burned, which results in reduced 'exposure to harmful chemicals' (pp. 31, 34) and 'the absence of smoke and second-hand smoke' (p. 37). 28 For the four reduced risk messages, the report similarly concluded that the product was 'perceived to be a lower risk than conventional cigarettes' (pp. 40, 42, 44, 46) by 'reducing the production of harmful chemicals found in cigarette smoke and providing a possible chance of reducing the risk of tobacco-related diseases' (pp. 44, 46) . 28 The fact that PMI's report does not distinguish perception of reduced risk and reduced exposure provides additional evidence that reduced exposure claims are viewed as reduced risk claims.
The findings from the second qualitative study (THS-PBA-04-US) that assessed reduced risk and reduced exposure claims in the context of marketing materials (brochure, pack and direct mail) portray a similar picture. The study report concludes that "There is a clear recognition that this is an innovative product that heats, rather than burns, the tobacco using electronic technology combining the tobacco taste satisfaction of CC's [conventional cigarettes] with hygiene benefits (less odor, no ash, less mess) and the potential to reduce the risk to health compared to smoking conventional cigarettes." 29 Also, "Understanding is generally consistent across all label, labeling and marketing material and subject groups." 29 In this second qualitative study, reduced exposure claims in combination with the information that IQOS does not reduce risk of tobacco-related disease (presented as 'Important Warning') were also perceived as confusing and contradictory, but still made participants rate the risk as moderate, below the Yet others were still very optimistic about the product that offers reduced risk, particularly appreciating the implications of reduced exposure as the ability to use HTPs in smoke-free places: "There's still a risk, so we all know we can't get anywhere besidesyou can't get anywhere, you can't even hide from that, so there's going to be risk. But it's just a better way of smoking a cigarette. It gives you a better option. 'Real tobacco, no fire, tobacco heating system', so obviously trying to make it a better way of smoking, make it better for you to smoke at your workplace, school, anywhere. So yeah, that's what I get from it. Well, they give you the less odor, no fire. It even tells you-it gives you a little hint that it will be better for the people that's around you worrying about affecting them, so that's good." (male adult smoker, 18-25 years old, Phoenix).
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In summary, PMI's qualitative studies demonstrate that US adults understand reduced exposure claim to mean that the lower levels of harmful chemicals in the product means reduced risk of health harms.
Quantitative studies
PMI reports results of two quantitative studies (THS-PBA-03-US and THS-PBA-05-REC-US, see table 2 for details) that were conducted by Covance Market Access Service. Quantitative studies were five-arm parallel group experiments, where each arm corresponded to the different message condition tested in the study. Studies used computer-assisted self-interviews (with computer-assisted personal interviews for more in-depth questions in THS-PBA-03-US) and lasted 45 min on average. The outcome measures used in these studies are presented in table 3. For the purpose of our study, we focus on the measures PMI used to assess global comprehension and risk perceptions because they indicate to what extent reduced exposure claims are perceived as reduced risk claims.
In THS-PBA-03-US, five different text-based messages were evaluated: four contained reduced exposure claims and one had a reduced risk claim (figure 1). Participants were randomised into five groups, where each group saw one of the messages. For the measure of global comprehension, the proportion selecting the answer 'Reduces the risk of tobacco-related diseases' was 18% for reduced exposure Message 3, 28% (Message 2), 32% (Message 1) and 35% (Message 4). For all perceived risk measures (health risk to self ( figure 3) , addiction risk and risk to others), participants rated IQOS lower in risk than cigarettes for all messages, whether it was a reduced exposure message or a reduced risk message.
In THS-PBA-05-REC-US, participants evaluated marketing materials with a reduced exposure warning: a brochure, a pack and a direct mail piece (figure 2). In this study, all materials had a reduced exposure claim, but it was paired with either a Surgeon General (SG) warning for cigarettes or a PMI-developed warning for IQOS communicating that reduced exposure does not mean reduced risk, that IQOS contains addictive nicotine and that IQOS can be harmful ('PMI Important Warning' in figure 2). Participants were randomised into five groups: (1) brochure with SG warning, (2) brochure with PMI warning, (3) pack with the SG warning, (4) pack with PMI warning and (5) direct mail piece with PMI warning.
Between 26% of participants (brochure with a PMI warning) and 58% (pack with SG warning) selected an answer that using IQOS reduces the risk of tobacco-related diseases for the global comprehension measure. An additional 0.8-2.6% answered that it 'eliminates the risk of tobacco-related diseases.' The proportion of participants who answered 'don't know' was 3.1-12.3%. In sum, a large proportion of participants who saw the reduced exposure messages selected answers indicating that tobacco-related disease risk is reduced by switching from cigarettes to IQOS.
For the measures of perceived risk to self, IQOS was rated lower than cigarettes. IQOS was rated similar in perceived risks to e-cigarettes for all measures of perceived risk ( figure 3) .
Participants also consistently rated IQOS as lower in perceived risk of addiction than combusted cigarettes, even though the marketing brochure did not contain any information on how IQOS compared with cigarettes in terms of addiction risk. PMI's report speculated that participants might be inferring lower perceived addiction risk for IQOS based on the information about reduced exposure to harmful chemicals. 30 PMI's study report 31 concluded, "In general, reduced exposure messages may present a greater challenge than reduced risk messages on comprehension of disease risk" (p. 74). "It appears likely that consumers will typically infer a degree of reduced disease risk, even where such inferences are explicitly contradicted by warning statements" (p. 76). 31 The report suggested that reduced exposure claims for IQOS "may present an apparent contradiction between (1) reductions in HPHCs [harmful or potentially harmful chemicals identified by the FDA in conventional cigarettes] and (2) a lack of reduced risk for disease" where participants have a hard time reconciling these claims. The report referred the FDA MRTP Draft Guidance, which also acknowledged that "there may be challenges to constructing appropriate claim language that conveys the potential benefits of the product to tobacco users and does not convey that the product is less harmful than other tobacco products. 9 In summary, PMI's quantitative studies corroborated the findings from qualitative studies that US adults perceive reduced exposure claims as reduced risk claims.
dIsCussIon
PMI proposed to market IQOS with reduced exposure and reduced risk claims in the USA. PMI's own qualitative and quantitative studies consistently show that reduced exposure claims are likely to be perceived as reduced risk claims and will, therefore, mislead the public. While few studies outside the tobacco industry evaluated consumer perceptions of reduced risk or reduced exposure claims for non-cigarette tobacco products, [32] [33] [34] the results were similar. El-Toukhy et al 34 found that modified exposure claims reduced perceived risks of snus and e-cigarette products among adults and adolescents. These results indicate that perceptions of exposure and risk are highly correlated and communication about one-either lower risk or lower exposure-reduces perceptions of both risk and chemical exposure.
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The conclusion that consumers interpret reduced exposure information as reduced harm seems to hold across different contexts and tobacco products. The tobacco industry's 'reduced exposure' claims are perceived as indicators of lower harm, as demonstrated by the PMI's studies reviewed here and by research on 'light' and 'mild' descriptors. 16 17 Furthermore, studies on different ways to communicate amounts of harmful chemicals in cigarettes consistently show that consumers misinterpret quantities of harmful chemicals as indicators of health risks. 35 36 This misperception holds regardless of the way the information on reduced exposure is presented: graphically, numbers only, or numbers with additional information, such as common use of these chemicals. 37 The tobacco industry has a long history of using reduced exposure claims to mislead consumers into believing that the products in question have reduced risk, most notably through the use of 'light' and 'mild' cigarette claims. 24 Therefore, it is particularly important that the FDA and comparable authorities elsewhere in the world take care not to give legal sanction for PMI or other tobacco companies to market their IQOS or other similar products to mislead the public in the same way that it and other tobacco companies have done with earlier products. In particular, IQOS and other HTPs should not be permitted to be marketed with labelling or advertising that claims or implies modified exposure because the PMI's own studies demonstrate that consumers perceive reduced exposure claims as reduced risk claims. Both US law (FSPTCA, 911(g) and 903) 10 Guidelines for Implementation 39 prohibit tobacco product labelling that is false or misleading, especially labelling that would mislead consumers to believe that the product is less harmful than other products. 40 Even though tobacco companies almost never marketed light and mild cigarettes with explicit claims of reduced health risks, promotions focused on reduced exposure (lower tar and nicotine) made smokers believe they were reducing their health risks
by switching to light cigarettes. [13] [14] [15] [16] [17] Later, tobacco companies went further to promote light and mild cigarettes with aspirational messages, linking light cigarettes to highly desirable places and situations, such as style, relaxation and sophistication. 41 PMI is using the same playbook in marketing IQOS around the world by promoting IQOS as sophisticated and aspirational, 7 emphasising the themes of cleanliness, customisation and sociability. 6 Based on what we have learnt from marketing of light cigarettes and natural tobacco, [42] [43] [44] as well as the results of PMI's own research, it is likely that these claims will also be understood by consumers as reduced risk claims. 34 
limitations and directions for future research
We report findings from PMI's qualitative and quantitative studies, relying primarily on the summary reports for each study rather than re-analysing the raw data. Our study is limited by the shortcomings of the original studies. For example, it is possible that participants in the qualitative studies perceived reduced exposure claims as reduced risk claims in part because they were exposed to all claims during their focus groups or interviews. These studies focused on more intensive message processing under conditions of participants paying attention to the messages. In the real world, these claims might be processed differently, and the resultant perceptions might be different. Future research should investigate how understanding of reduced exposure and reduced risk claims varies under situations of limited attention and unmotivated processing. Combining reduced risk/exposure claims with warning information that comes from a different source (such as the government) might result in differential processing by various people and more studies need to be done with warnings attributed to various sources to evaluate whether the findings were the artefacts of these specific claims.
Another area worth examining is the role of the source of modified risk information. The PMI's studies do not report on who the consumers attributed the claims to; however, given what we know, understanding whether consumers think this information comes from FDA or from tobacco companies would play an important role. Past research found that consumers (including tobacco users) generally trust FDA and generally distrust tobacco companies. 45 Furthermore, attributing reduced risk claims to FDA might make consumers mistakenly believe that the government endorsed these products and further reduce their risk perceptions, resulting in less informed decision making in the marketplace. 33 ConClusIon PMI's MRTP application for IQOS makes reduced risk claims about IQOS that, like its earlier 'light' and 'mild' claims that were deemed fraudulent in the RICO case, are not substantiated by PMI's own internal research reported in its application. [2] [3] [4] Several of the other papers in this supplement indicate that IQOS is not significantly less harmful than combusted cigarettes 2-4 46 47 and that while IQOS had lower levels of pulmonary cytotoxicity 48 and carcinogens 49 than combusted cigarettes, they were higher than those of e-cigarettes. Therefore, the limited evidence on the health risks of HTPs does not support the much lower levels of perceived harm that PMI's consumer studies found. Even the evidence for the reduced exposure claim is questionable because PMI's data show higher levels of exposure than conventional cigarettes to some toxins. 2 In the MRPT application, PMI makes an argument that the 'reduction in exposure to toxicants provides the foundation for the reduced harm rationale for this product as an MRTP', which further indicates that they do not currently have evidence aside from the data on reduced emissions to demonstrate effects on health. However, this is exactly what FDA says is not sufficient to show reduced risk, that is, to demonstrate that IQOS 'significantly reduce[s] harm and the risk of tobacco-related disease to individual users.' On 25 January 2018, the FDA Tobacco Products Scientific Advisory Committee (TPSAC) voted not to accept Philip Morris' claims that IQOS is less harmful than cigarettes (with 8 'No's and 1 'Abstain'). The TPSAC found (on an 8 to 1 vote) that the evidence presented by PMI demonstrated its reduced exposure claim, but unanimously rejected the idea that PMI demonstrated that consumers accurately understand the risks of IQOS. The important point is that the evidence from consumer studies clearly indicates that even a reduced exposure claim does not meet the regulatory criteria because consumers will understand such a claim as a reduced risk claim.
PMI's reduced exposure claims in its labelling and marketing for IQOS and similar claims for HTPs made by other companies are likely to be misunderstood as reduced risk claims. Therefore, FDA and other regulatory agencies in other countries should not permit PMI or any other tobacco company to market IQOS with reduced exposure claims. If PMI and other tobacco companies are allowed to make confusing (if not deliberately deceptive) claims in its labelling and/or advertising, it is likely to result in consumers being misled into believing HTPs are endorsed by regulatory agencies or into misunderstanding HTP's harmfulness. 50 In short, despite PMI's contradictory statements, 26 the actual reports, transcripts and data submitted by PMI to FDA provide substantial evidence that consumers perceive reduced exposure claims as reduced risk claims. Allowing PMI to promote IQOS as reduced exposure would amount to a legally sanctioned repeat of the 'light' and 'mild' fraud which, for conventional cigarettes, is prohibited by the US law and the FCTC.
What this paper adds ► The US Food and Drug Administration can authorise marketing of tobacco products as causing less exposure to harmful chemicals or lowering health risks. The law requires that claims of lower exposure do not mislead the public into believing the product presents reduced risk of health harm. ► The evidence in Philip Morris International's qualitative and quantitative studies submitted as part of its modified risk tobacco product application reveals that adult consumers in the USA perceive reduced exposure claims as reduced risk claims. ► Without evidence of reduced risk, claims of lower exposure are inherently misleading because they will be interpreted as reduced risk claims even if they do not explicitly make reduced risk claims.
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